Network Insights Methodology Whitepaper Get Access

AstraZeneca

ORG Health Care / Pharmaceuticals Momentum 7.8ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$81.5B market cap (London-listed). AstraZeneca develops oncology, cardiovascular, respiratory, and immunology drugs. Terminated $400B Bristol Myers merger exploration in 2026; investors dumped stock over failed US tie-up talks.

Explored but terminated merger discussions with Bristol Myers Squibb valued at approximately $400B. Active in strategic partnerships including deals with Pathos and China's Alphamab.
0.85
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
7.8
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
30
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
AstraZeneca is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
FDA United Kingdom China European Union PlocamiumAI Wall Street Merck Eli Lilly Novartis Financial Times Europe Bloomberg Novo Nordisk Paris Nasdaq
Watch This Entity
PSI Intelligence
30-Day Trend
2026-07-15 2026-08-14 30 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
214.804
Sentiment-Momentum Divergence
0.000
Source Concentration
0.387
Signal
AstraZeneca is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #3 of 73 in Health Care — sector outlier (2.2 sigma above median). PSI up 0.14 from yesterday (0.82 -> 0.96).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
3 of 73
Sector Rank
+2.18
Peer Z-Score
97%
Sector Percentile
Network Analysis
30 Degree Centrality
Ego Network (top connections)
FDA (weight 32.0)United Kingdom (weight 19.0)China (weight 13.0)European Union (weight 13.0)PlocamiumAI (weight 11.0)Wall Street (weight 11.0)Merck (weight 9.0)Eli Lilly (weight 8.0) FDAUnited KingdomChinaEuropean UnionPlocamiumAIWall StreetMerckEli Lilly AstraZeneca (degree 30) AstraZeneca
Centrality History
2026-07-15 2026-08-14 30 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 32 NEW
United Kingdom 19 NEW
China 13 NEW
European Union 13 NEW
PlocamiumAI 11 NEW
Wall Street 11 NEW
Merck 9 NEW
Eli Lilly 8 NEW
Novartis 8 NEW
Financial Times 6 NEW
Europe 4 NEW
Bloomberg 4 NEW
Novo Nordisk 4 NEW
Paris 3 NEW
Nasdaq 3 NEW
Supreme Court 3 NEW
Alphabet 3 NEW
Reuters 3 NEW
London 3 NEW
Anthropic 3 NEW
White House 2 NEW
Yahoo 2 NEW
Iran 2 NEW
England 2 NEW
DOJ 2 NEW
Japan 2 NEW
Senate 2 NEW
Florida 2 NEW
Texas 2 NEW
LONDON 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-08-14 ← Intelligence Network